Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sheldon L. Koenig | President, CEO & Director | 1.28M | -- | 1966 |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | 718.86k | -- | 1972 |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer | -- | -- | 1986 |
| Mr. Glenn P. Brame | Chief Technical Operations Officer | -- | -- | 1958 |
| Mr. Benjamin O. Looker J.D. | General Counsel & Corporate Secretary | 550.35k | -- | 1982 |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications | -- | -- | -- |
| Ms. Betty Jean Swartz | Chief Business Officer | -- | -- | -- |
Esperion Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 240
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Corporate Governance
Upcoming Events
February 25, 2025 at 1:30 PM UTC - March 3, 2025 at 1:30 PM UTC
Esperion Therapeutics, Inc. Earnings Date